Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05271318
Title Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors TILT Biotherapeutics Ltd.

fallopian tube cancer

ovarian cancer

peritoneum cancer


Pembrolizumab + TILT-123

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.